CJC 1295 (Mod GRF 1-29)

CJC-1295 with DAC (Drug Affinity Complex) is a synthetic growth hormone–releasing hormone (GHRH) analog designed to stimulate the body’s natural production of growth hormone (GH). Unlike short-acting GHRH peptides, the DAC modification allows the peptide to bind to albumin in the bloodstream, significantly extending its half-life and duration of activity. Originally developed for research into hormone deficiencies and metabolic disorders, CJC-1295 with DAC is now widely studied in performance optimization, anti-aging, and body composition protocols. By promoting sustained growth hormone release and increasing insulin-like growth factor-1 (IGF-1), the peptide may support muscle recovery, fat metabolism, sleep quality, and tissue repair. Because it stimulates endogenous hormone production rather than supplying synthetic growth hormone directly, CJC-1295 with DAC is often viewed as a more physiologic method of enhancing the GH–IGF-1 axis.